
ASX ANNOUNCEMENT

25 November 2024

Anteris Technologies Global Corp. files Registration Statement for Proposed US Initial Public Offering

Anteris Technologies Ltd (ASX: AVR) (ATL, Anteris or the Company) is pleased to advise that Anteris Technologies Global Corp. (**ATGC**) has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (the **SEC**), relating to the proposed initial public offering of ATGC's common stock (**Common Stock**) in the U.S (the **Offering**). All Common Stock to be sold in the Offering will be offered by ATGC.

The amount of Common Stock to be offered and the price range for the proposed Offering have not yet been determined. The Offering is subject to market conditions and there can be no assurances as to whether or when the Offering may be completed, or as to the actual size, price or other terms of the Offering.

Following the re-domiciliation of Anteris and its subsidiaries (the **Anteris Group**) to the United States, by way of the proposed schemes of arrangement between ATL and ATL shareholders and ATL optionholders (the **Schemes**), ATGC intends to list its Common Stock on the Nasdaq Global Select Market under the symbol "AVR."

ATL securityholders should refer to the Scheme Booklet and Supplementary Scheme Booklet issued by ATL for further information in relation to the Schemes, including the advantages and disadvantages of the Schemes.

Following the Offering, ATGC intends to list its CHESS Depositary Interests (**CDIs**) (representing underlying shares of Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the Australian Securities Exchange under the symbol "AVR".

TD Cowen, Barclays and Cantor are acting as joint book-running managers for the proposed Offering, with Lake Street Capital Markets acting as lead manager. Bell Potter is acting as a financial adviser in relation to the participation of certain potential Australian investors in the Offering.

The proposed Offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus relating to the proposed Offering may be obtained from: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at +1 (855) 495-9846 or by e-mail at TD.ECM_Prospectus@tdsecurities.com; Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at +1 (888) 603-5847 or by e-mail at Barclaysprospectus@broadridge.com; or Cantor, 110 East 59th Street, 6th Floor, New York, NY 10022, by telephone +1 (212) 915-1800 or by e-mail at prospectus@cantor.com.

A registration statement relating to the Common Stock has been filed with the SEC but has not yet become effective. The Common Stock may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

This announcement is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy the Common Stock, and shall not constitute an offer, solicitation or sale of the Common Stock in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

ENDS

About ATGC

ATGC was incorporated on January 29, 2024 for the purpose of reorganizing the operations of Anteris Technologies Ltd (“Anteris”), an Australian public company originally registered in Western Australia, Australia and listed on the Australian Securities Exchange (“ASX”), into a structure whereby the ultimate parent company will be a Delaware corporation.

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR®, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR® THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR® THV is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR® Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR® THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.

Authorisation and Additional information

This announcement was authorised by the Board of Directors of Anteris.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech

